Estimation of seroprevalence of HIV, hepatitis B and C virus and syphilis among blood donors in the hospital of Aïoun, Mauritania

Boushab Mohamed Boushab1, Ould Cheikh Melaïnine Mohamed Limame2, Fall-Malick Fatim Zahra3, Savadogo Mamoudou4, Belizaire Marie Roseline Darnycka5, Sow Mamadou Saliou6

1Department of Internal Medicine, Aïoun Regional Hospital, Hodh El Gharbi, Mauritania, 2Ambulatory Treatment Center, National Hospital Center of Nouakchott, Mauritania, 3National Institute of Hepatology-Virology in Nouakchott, School of Medicine, Nouakchott, Mauritania, 4Department of Infectious Diseases, University Teaching Hospital Yalgado Ouédrago, Ouagadougou, Burkina Faso, 5Health Security and Emergency Officer, WHO World Health Emergency Programme, Mauritania, 6Department of Infectious Diseases, University Teaching Hospital Donka, Conakry, Guinée

6Corresponding author: Boushab Mohamed Boushab, Department of Internal Medicine, Aïoun Regional Hospital, Hodh El Gharbi, Mauritania

Key words: Seroprevalence, HIV, hepatitis B, hepatitis C, syphilis, blood donors, Aïoun? Mauritania

Received: 24/04/2017 - Accepted: 11/08/2017 - Published: 06/10/2017

Abstract

Introduction: to estimating the seroprevalence of HIV, hepatitis B, hepatitis C and syphilis among blood donors in the Aïoun hospital.

Methods: this is a retrospective study from 1 January 2010 to 31 December 2015. Results: on the five-year study period, 1,123 donors were collected. Of these, 182 were HIV-positive, an overall prevalence of 16.2% with predominance in male with a sex ratio Man/Woman of 5.2. The average age of donors was 32.7 ± 10 years (range 17-73 years). The most represented that age group 21-30 years (40.5%). The seroprevalence found were 1.2% for HIV, 11.8% for HBV, HCV 0.2% and 3% for syphilis. Co-infection was found in 0.7% of which 0.5% of dual HIV HBV/Syphilis and 0.2% in HBV/HIV. Conclusion: the transmission of infectious agents related to transfusion represents the greatest threat to transfusion safety of the recipient. Therefore, a rigorous selection and screening of blood donors are highly recommended to ensure blood safety for the recipient.
Introduction

Blood transfusion is a medical therapeutic act [1-3]. However, despite the benefits, each patient is transfused at risk for transfusion-transmissible infections, mainly HIV, hepatitis B (HBV), hepatitis C (HCV) and Treponema pallidum (T. pallidum) [2, 3]. The morbidity and mortality resulting from transfusion have serious consequences, not only for the beneficiaries themselves but also for their families, their communities and society in general [3-4]. Studies conducted in sub-Saharan Africa show that there is a high prevalence of these infections [3-12]. In Mauritania, studies of prevalence among blood donors held in Nouakchott in 1999, 2000 and 2009 showed respective HCV seroprevalence of 1.1% and 2.7% [11, 13] HBV and 15.3% and 20.3% [11, 14]. This study has aimed to update the seroprevalence data of 4 serological markers (HIV, HBV, HCV, anti-Ag-Treponema pallidum) tested in blood donors from the Hospital Aioun, in accordance with national strategy for patient safety.

Methods

This is a retrospective descriptive study among blood donors in the regional hospital Aioun, Hodh El Gharbi (Mauritania), over a period of 5 years from January 1 2010 to 31 December 2015. This hospital is the reference center of the Hodh El Gharbi region (Mauritania) and welcomes an urban and rural population. Aioun el Atrouss (62,984 inhabitants) is the administrative capital of the wilaya of Hodh El Gharbi (288,772 inhabitants). Wilaya is located 800 km from Nouakchott (capital) South-East of the country and has the only regional hospital specific reference to medical care and/or surgery which offers the public a range of treatments specifically in the areas of dentistry, general medicine, surgery, obstetrics and ophthalmology. Donors were either volunteers or relatives or friends of patients apparently healthy weighing 50 kg or more with a hemoglobin > 12.5 g/dL. Before every donation, sorting through a donor questionnaire stage, a complete physical examination, serologic screening of the major transfusion transmissible infections and ABO grouping. The confidentiality of donors was met, as the anonymity of the gift obliges. No information revealing their identity was collected in this study. The parameters studied were sex, age, serology for HIV, HBV, HCV and syphilis. Mark of HBV HbsAg was performed using an immunochromatographic test, Determine™ HbsAg Test (AlereMedical Co. Ltd, Japan). The demonstration of antibodies to HIV and those anti-HCV-Ab were carried out respectively by the test, Determine™ HIV-1/2 (Alere Medical Co. Lt, Japan) and the Rapid test SignalMT HCV Serum/Plasma Dipstrip Test for the hepatitis C (Alerehealthcare, South Africa). Seropositivity for syphilis in turns uses a completely screening by a Rapid-Plasma-Réagin test (syphilis RPR test, Human Gesellschaft für Biochemical diagnosis and H, Germany) then the positive samples were passed to the TPHA (Treponema Pallidum Hemagglutination Assay) and the Venereal Disease Research Laboratory (VDRL), for confirmation. Entry and data analysis were performed using Epi Info version 6.4 software. For the comparison of quantitative variables the Chi-square test was used. A p value < 0.05 was selected as the significance threshold.

Results

Over the study period of 5 years, in 1123 donors were collected. The male was predominant, with a ratio sex- Male/Female 5.2. The average age of donors was 32.7 ± 10 years (range 17-73 years). Up to 20 years old and the age group 21 to 30 years, respectively represented 11% and 40.5% of donors. The age group of 31 to 40 accounted for 26.8% and the 41 to 50 years 14.7%. The age group 51 and older accounted for 7% of donors. Considering all the markers, 182 among the donors presented seropositivity, an overall prevalence of 16.2%. The prevalence of HIV, HBV, HCV and syphilis were observed in 1.2%, 11.8%, 0.2% and 3%. Co-infection was found in 0.7% of cases and 0.5% of dual-infection HBV/Syphilis and 0.2% in the double HBV/HIV infection. A statistically significant difference was observed between HBV carriage and the most affected age group (p = 0.009) and between syphilis and age groups (p = 0.02) (Table 1).

Discussion

The findings of this study reflect a general idea about the prevalence of infectious markers in a rural hospital with very limited means. The results can therefore only be interpreted within these limits. However, they highlight a greater representation of men with a sex-ratio Male/Female 5.1. This male predominance may be explained by socio-cultural markers making man the ideal candidate to for blood donation. On gynéco of obstetric physiological factors such as menstrual cycles, pregnancy, breastfeeding can also reinforce this trend. These factors may indeed encourage many women to not donate blood [15]. This male was already provided by other African writers in Nigeria, Mali, Niger, Ivory Coast and Cameroon [4-6, 16, 17]. The average age of our donors was similar to that reported by other African studies in Mali, Nigeria and Cameroon [4, 5, 6, 17]. In our study, the overall prevalence of biomarkers studied in blood donors was 16.2%. This percentage is lower than that reported by other African writers in Burkina Faso, Nigeria, Niger, Cameroon and Tanzania [3, 4, 6, 7, 9]. The most represented age group was the 21 to 30 years. These results are similar to those in other african study [3, 8, 9, 18, 19]. HIV seroprevalence reported as part of this study was 11.8%. This proportion was lower than previously reported in studies conducted in Nouakchott in 1999 and 2012 [11, 14]. It was also lower than those made in the african sub-region, including Mali [20], in Sénégal [21], in Burkina Faso [9], in Niger [6], Ivory Coast [16] and in Nigeria [19] but was higher than those made in Morocco [22], in Ethiopia [8], in Tanzania [7], Democratic Republic of Congo (DRC) [10] and Cameroon [3, 17]. HVC, the prevalence was 0.2%.

This figure was lower than previously found in a study conducted in 1999 and 2007 in Nouakchott [11, 13], as well as those reported in studies African countries [3, 4, 6-9, 17, 20, 22-26]. In our study, HIV seroprevalence was 1.2%. These figures are higher than the estimated national prevalence was 0.4% [27]. This prevalence is higher than those made in Morocco and Algeria [28, 29]. As against it remains lower than those reported in Mali, Burkina Faso, Niger, Ivory Coast, Nigeria, Ethiopia, Tanzania, DRC and Cameroon [3, 4, 6, 10, 16, 17, 20]. The prevalence of syphilis was 3%. These figures are lower than those found in other studies in Africa, including Burkina Faso, Tanzania, DRC and Cameroon [3, 8, 10, 17] but it remains higher than those reported in Mali, Niger, Nigeria and Ethiopia [4, 6, 8, 20]. As regards co-infections, associations HBV/HIV and HBV/syphilis were observed in respectively 0.2% and 0.5% of cases. As indiquépar other studies, this association could be due to the fact that these infections share similar transmission, mainly blood and sexual behavior at high risk of infection [4, 8, 30]. Other studies have shown an association between HIV and syphilis, probably because of their sexual mode of transmission similar especially that the mucocutaneous lesions caused by syphilis is a gateway to HIV infection [8, 31]. In our study the seroprevalence of HIV, HBV and syphilis were the highest in the different age groups in comparison with other markers (HCV and syphilis studied).
Conclusion

Despite enormous progress in the framework of transfusion safety, blood transfusion is a medical therapeutic act which exposes the recipient to a risk of contamination by infectious agents transmissible through blood. Therefore, to enhance good blood safety for the recipient, it is necessary to focus on a rigorous selection and retention of donors on the one hand and the use of screening methods standards minimizing the window period. Furthermore, studies on the residual risk to measure the likelihood of transmission of various infectious agents by blood products, are entirely justified, especially for HBV, which is a real public health problem in our context, with prevalence approaching 20% in different groups (surveys conducted among different groups between 2007 and 2009).

What is known about this topic

- Blood transfusion is a medical therapeutic act;
- Each patient is transfused at risk for transfusion-transmissible infections if the blood is not secured;
- The morbidity and mortality resulting from transfusion have serious consequences for patients, communities and society in general.

What this study adds

- To our knowledge, this study is the first in the country to study these 4 markers at the same time;
- Estimating the seroprevalence of infectious markers in blood donors;
- To strengthen transfusion safety in recipients since there are only intra-family donors in most cases.

Competing interests

The authors declare no competing interests.

Authors’ contributions

Mohamed Boushab Boushab: he has been involved in drafting the manuscript, made substantial contributions to study conception and design, clinical data verification, discussion section: Ould Cheikh Melainine Mohamed Limame; manuscript correction; Fatim-Zahra; Malick Fall, manuscript correction; Mamoudou Savadogo; manuscript correction. Belzaint, Marie Roseline Darnycka; manuscript correction; Mamadou Salou Sow; manuscript correction. All authors have read and approved the final manuscript.

Table

Table 1: Comparing age groups of infected and non-infected blood donors 194

References

1. Choudhury N. Transfusion transmitted infections: how many more. Asian J Transfus Sci. 2010; 4(2): 71-2. PubMed | Google Scholar
2. Shrestha AC, Ghimire P, Tiwari BR, Rajkarnikar M. Transfusion-transmissible infections among blood donors in Kathmandu, Nepal. J Infect Dev Ctries. 2009; 3(10): 794-7. PubMed | Google Scholar
3. Noubiap JJN, Joko WYA, Nansseu JRN, Tene UG, Siaka C. Sero-epidemiology of human immunodeficiency virus, hepatitis B and C viruses and syphilis infections among first-time blood donors in Edéa, Cameroon. Int J Infect Dis. 2013; 17(10): e832-7. Google Scholar
4. Buseri FJ, Muhibi MA, Jeremiah ZA. Sero-epidemiology of transfusion-transmissible infectious diseases among blood donors in Osogbo, south-west Nigeria. Blood Transfus Trasf Sangue. 2009; 7(4): 293-9. PubMed | Google Scholar
5. Koné MC, Sidibé ET, Mallé KK, Beye SA, Lurton G, Dao S et al. Séroprévalence des virus de l’immunodéficience humaine et des hépatites B et C chez les donneurs de sang à Ségu (Mali). Méd Santé Trop. 2012; 22(1): 97-8. Google Scholar
6. Mayaki Z, Dardenne N, Kabo R, Moutschen M, Sondag D, Albert A et al. Séroprévalence des marqueurs de l’infection chez les donneurs de sang à Niamey (Niger). Rev Dépidémiologie Santé Publ. 2013; 61(3): 233-40. Google Scholar
7. Matee MIN, Magesa PM, Lyamuya EF. Seroprevalence of human immunodeficiency virus, hepatitis B and C viruses and syphilis infections among blood donors at the Muhimbili National Hospital in Dar es Salaam, Tanzania. BMC Public Health. 2006; 6: 21. Google Scholar
8. Tessema B, Yismaw G, Kassu A, Amsalu A, Mulu A, Emmrich F et al. Seroprevalence of HIV, HBV, HCV and syphilis infections among blood donors at Gonder University Teaching Hospital, Northwest Ethiopia: declining trends over a period of five years. BMC Infect Dis. 2010; 10: 111. Google Scholar
9. Nagalo BM, Bisseye C, Sanou M, Kienou K, Nebié YK, Kiba A et al. Seroprevalence of hepatitis B and C viruses and syphilis infections among blood donors from regional blood transfusion centres in Burkina Faso, West Africa. Trop Med Int Health. 2012; 17(2): 247-53. PubMed | Google Scholar
10. Batina A, Kabomba S, Malengela R. Infectious markers among blood donors in Democratic Republic of Congo (DRC). Rev Méd Brux. 2007; 28(3): 145-9. PubMed | Google Scholar
11. Lo BB, Meymouna M, Boulahi MA, Tew M, Sow A, Ba A et al. Prevalence of serum markers of hepatitis B and C virus in blood donors of Nouakchott, Mauritania. Bull Société Pathol Exot. 1999; 92(2): 83-4. PubMed | Google Scholar
12. Candotti D, Sarkodie F, Allain JP. Residual risk of transfusion in Ghana. Br J Haematol. 2001; 113(1): 37-9. PubMed | Google Scholar

13. Ayé MO, Moktar MM. Épidémiologie de l’hépatite C en Mauritanie. J Afr Hépato-Gastro. 2008; 1(3-4): 141-2. Google Scholar

14. Mansour W, Bollahi M-A, Hamed C-T, Brichler S, Le Gal F, Ducancelle A et al. Virological and epidemiological features of hepatitis delta infection among blood donors in Nouakchott, Mauritania. J Clin Virol. 2012; 55(1): 12-6. PubMed | Google Scholar

15. Tagny CT, Owusu-Ofori S, Mbanya D, Deneys V. The blood donor in sub-Saharan Africa: a review. Transfus Med Oxf Engl. 2010; 20(1): 1-10. PubMed | Google Scholar

16. Kra O, N'Diri N, Ehui E, Ouattara B, Issagene N. Prevalence of HBeAg in blood donors in the Bouaké regional centre of blood transfusion in 2001. Bull Société Pathol Exot. 2007; 100(2): 127-9. PubMed | Google Scholar

17. Moukoko CEE, Sack FN, Same EGE, Mbangue M, Lehman LG, HIV, HBV, HCV and T. pallidum infections among blood donors and Transfusion-complicated infections among recipients at the Laquintinie hospital in Douala, Cameroon. BMC Hematol. 12 2014; 14(1): 5. Google Scholar

18. Nzaji MK, Ilunga BK. A study of the prevalence of infectious markers in blood donors in rural areas: the case of Kamina hospital. Santé Pub. 2013; 25(2): 213-7. PubMed | Google Scholar

19. Bisseye C, Sanou M, Nagalo BM, Kiba A, Compaoré TR, Tao I et al. Epidemiology of Syphilis in regional blood transfusion centres in Burkina Faso, West Africa. Pan Afr Med J. 2013; 16: 69. PubMed | Google Scholar

20. Diarra A, Kouriba B, Baby M, Murphy E, Lefrere J-J. HIV, HCV, HBV and syphilis rate of positive donations among blood donations in Mali: lower rates among volunteer blood donors. Transfus Clin Biol J Société Fr Transfus Sang. 2009; 16(5-6): 444-7. PubMed | Google Scholar

21. Vrav M, Debonne J-M, Sire J-M, Tran N, Chevalier B, Plantier J-C et al. Molecular epidemiology of hepatitis B virus in Dakar, Sénégal. J Med Virol. 2006; 78(3): 329-34. PubMed | Google Scholar

22. Baha W, Foulous A, Dersi N, They-they TP, El alaoui K, Nourichi N et al. Prevalence and risk factors of hepatitis B and C virus infections among the general population and blood donors in Morocco. BMC Public Health. 2013; 13: 50. PubMed | Google Scholar

23. Dieye TN, Gadji M, Cisse Y, Diallo TA, Toure Falla O, Diop S et al. Seroprevalence of hepatitis C virus (HCV) in Senegal. Transfusion clin. 2006; 51(1): 47-52. PubMed | Google Scholar

24. Mohamoud YA, Mumtaz GR, Rione S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis. 2013 June 24; 13: 286. PubMed | Google Scholar

25. Abid S, Fikih S, Khlass B, Cherif W, Tourni NH, Jenhani F et al. Screening and confirmation of anti-HCV antibodies in Tunisian blood donors. Transfus Clin Biol J. 1997; 4(2): 221-6. PubMed | Google Scholar

26. Ayed Z, Houinato D, Hocine M, Ranger-Rogez S, Denis F. Prevalence of serum markers of hepatitis B and C in blood donors and pregnant women in Algeria. Bull Société Pathol Exot 1990. 1995; 88(5): 225-8. PubMed | Google Scholar

27. Fall-Malick FZ, Bara AO, Lam M, Mint Beibacar M, Ba K, Ba H et al. HIV sentinel surveillance of pregnant women in Mauritania from 2001 to 2007. Bull Société Pathol Exot 1990. 2010; 103(4): 243-5. PubMed | Google Scholar

28. Elmir E, Nadia S, Ouafae B, Rajae M, Amina S, Rajae EA. HIV epidemiology in Morocco: a nine-year survey (1991-1999). Int J STD AIDS. 2002; 13(12): 839-42. PubMed | Google Scholar

29. Al-Kakil B, Belabes E, Bouguermouch A, Aouati A, Smati1 F. Aspects seroepidemiologiques de l’infection a VIH en Algérie. Sci Technol C. 2004; 22: 7-10. Google Scholar

30. Iroezindu MO, Danyiam CA, Agbaji OO, Isa ES, Okeke EN, Imade GE. Prevalence of hepatitis B e antigen among human immunodeficiency virus and hepatitis B virus co-infected patients in Jos, Nigeria. J Infect Dev Ctries. 2013 Dec 15; 7(12): 951-9. PubMed | Google Scholar

31. Grosskurth H, Moshu F, Todd J, Mwijarubi E, Klokke A, Senkoro K et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet. 1995; 346(8974): 530-6. PubMed | Google Scholar

### Table 1: Comparing age groups of infected and non-infected blood donors

| Age class | Blood donors | HBV | HCV | HIV | Treponema pallidum |
|-----------|--------------|-----|-----|-----|-------------------|
| <20       | 123          | 15  | 0   | 0   | 7                 |
| 21-30     | 455          | 63  | 4   | 19  |                   |
| 31-40     | 301          | 36  | 1   | 6   | 7                 |
| 41-50     | 165          | 6   | 0   | 1   |                   |
| >51       | 79           | 12  | 3   | 1   |                   |
| Total     | 1123         | 132 | 14  | 34  |                   |
| p         | 0.009        | 0.13| 0.08| 0.02|                   |